1. Clinical & Scientific Overview
Clobetasol Propionate (TIP-MED-000439, Reference Code [12.26]-C169) is classified under
Dermatological & Topical Antiseptic Preparations (Ch 12) as a Potent (Class II/III) Fluorinated Topical Corticosteroid.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [12.26] (Betamethasone Valerate & Clobetasol Propionate (Topical Steroids)). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.26], p. 167): Betnovate (0.1% Valerate), Diprovate (0.05% Dipropionate) — Strengths & Dosage Forms: Cream / Ointment / Scalp Lotion: Betamethasone Valerate 0.1% w/w; Betamethasone Dipropionate 0.05% w/w (alone or with Salicylic Acid 3% for hyperkeratotic plaques).
Cream / Ointment / Scalp Lotion: Betamethasone Valerate 0.1% w/w; Betamethasone Dipropionate 0.05% w/w (alone or with Salicylic Acid 3% for hyperkeratotic plaques).
3. Mechanism of Action & Pharmacodynamics
Binds cytoplasmic glucocorticoid receptors in keratinocytes and dermal leukocytes -> induces lipocortin-1 (annexin-1) -> inhibits phospholipase A2, NF-kB, pro-inflammatory cytokines, and capillary dilation.
4. Therapeutic Indications & Evidence-Supported Uses
- Steroid-responsive inflammatory dermatoses: chronic plaque psoriasis, lichen planus, severe atopic/nummular eczema, contact dermatitis, discoid lupus erythematosus
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Apply thinly (guided by Finger-Tip Unit: 1 FTU = ~0.5 g covers 2 adult handprints) once or twice daily for 1–2 weeks (up to 4 weeks on thick palms/soles), then taper or switch to emollient. • Paediatric: Avoid in infants <1 year; in older children, use only under dermatologist supervision for <=5-7 days without occlusion.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [12.26].
Renal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA axis suppression.
Renal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA axis suppression.
Renal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA axis suppression.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Untreated cutaneous bacterial, viral (herpes simplex, varicella), or fungal (tinea) infections; rosacea; acne vulgaris; perioral dermatitis; routine use on face, groin, or axillae. • Precautions: SEVERE TOPICAL STEROID MISUSE EPIDEMIC IN INDIA: Never dispense or recommend Betnovate as a fairness cream, acne cream, or groin ringworm cream—facial/intertriginous use causes irreversible skin atrophy, telangiectasia, steroid rosacea, perioral dermatitis, hypertrichosis, and tinea incognito! Application of >50 g/week or under occlusive dressings suppresses the hypothalamic-pituitary-adrenal (HPA) axis and causes iatrogenic Cushing's syndrome.
Key Clinical Precautions: Renal: No adjustment. • Hepatic: Extensive systemic absorption over large body surface area in liver failure can cause HPA axis suppression.
8. Adverse Effects Profile
- Skin thinning (epidermal/dermal atrophy), striae distensae (stretch marks), telangiectasia, hypopigmentation, contact folliculitis.
- Adrenal suppression / Cushing's syndrome (extensive/occluded use), glaucoma/cataracts (periocular application), rebound pustular psoriasis on abrupt cessation.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Concurrent systemic corticosteroids -> additive HPA axis suppression
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.26].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Use the Finger-Tip Unit (FTU) rule to apply a very thin layer to the affected eczema/psoriasis patch only; NEVER apply on the face, groin, or fungal ringworm; apply moisturisers 30 minutes apart.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Cream / Ointment / Scalp Lotion: Betamethasone Valerate 0.1% w/w; Betamethasone Dipropionate 0.05% w/w (alone or with Salicylic Acid 3% for hyperkeratotic plaques).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.27] Povidone-Iodine (5% / 10% Antiseptic Solution, Ointment & Gargle) — Broad-Spectrum Iodophor Antiseptic & Disinfectant
- [12.28] Chlorhexidine Gluconate (0.2% Mouthwash & 4% Surgical Scrub) — Cationic Bisbiguanide Antiseptic & Disinfectant (Persistent Resid
- [12.29] Silver Sulfadiazine (1% Topical Burn Antimicrobial Cream) — Topical Heavy-Metal / Sulfonamide Burn Antimicrobial
- [12.6]-C153 Nadifloxacin — Topical Corticosteroids (Grouped by Potency: Super-Potent Clobeta